Alder Biopharmaceuticals, based in Bothell, Washington, uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics.
Today the company is actively engaged in developing its own proprietary therapeutics and enabling partners through out-licensing of its technologies. Their first drug candidate is ALD518, a humanized monoclonal antibody that blocks the inflammatory protein IL-6. Alder entered into an agreement with Bristol-Myers to co-develop ALD518 for rheumatoid arthritis but has retained the commercial rights for its use in cancer-related conditions. Additional promising pipeline products include a treatment for migraines that has just entered the clinic and an anti-PCSK9 antibody that has been shown preclinically to reduce cholesterol levels.
For more information visit:
Today the company is actively engaged in developing its own proprietary therapeutics and enabling partners through out-licensing of its technologies. Their first drug candidate is ALD518, a humanized monoclonal antibody that blocks the inflammatory protein IL-6. Alder entered into an agreement with Bristol-Myers to co-develop ALD518 for rheumatoid arthritis but has retained the commercial rights for its use in cancer-related conditions. Additional promising pipeline products include a treatment for migraines that has just entered the clinic and an anti-PCSK9 antibody that has been shown preclinically to reduce cholesterol levels.
For more information visit:
Total raised: $38M
Investors 5
| Date | Name | Website |
| - | H.I.G. Cap... | higcapital... |
| - | Ridgeback ... | ridgebackc... |
| - | TPG | tpg.com |
| - | Delphi Ven... | delphivent... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.04.2012 | Series D | $38M | - |
Mentions in press and media 12
| Date | Title | Description |
| 24.10.2024 | Jade Biosciences Extends Financing; Total To $95M | Jade Biosciences, a Vancouver, BC, Canada-based biotechnology company dedicated to developing therapies for patients living with autoimmune diseases, extended its financing, bringing the total raised to $95M. The round added Frazier Life Sc... |
| 16.09.2019 | Lundbeck to acquire Alder BioPharmaceuticals for nearly $2B | Alder’s lead drug candidate is eptinezumab, a monoclonal antibody for migraine prevention that targets the calcinonin gene-related peptide, or CGRP, and has been submitted to the FDA for approval, with the agency expected to rule on the dru... |
| 16.09.2019 | Lundbeck to Buy Alder BioPharmaceuticals, For Up To USD 1.95 Billion | H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY), a Valby, Denmark-based global pharmaceutical company specialized in brain diseases, is to acquire Alder BioPharmaceuticals (NASDAQ: ALDR), a Bothell, Washington, USA-based company committed to advanc... |
| 29.01.2018 | Roche touts CHMP nod for Hemlibra; Alder raises $200M for migraine drug launch | → Roche’s $RHHBY Hemlibra has just scored a positive opinion from CHMP, as it continues to tout the hemophilia drug as a potential blockbuster. The committee, whose recommendations are usually adopted by the Europea... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 09.01.2013 | A biopharma startup’s antibody goes for migraine headache trigger finger | Latham said the company’s goal for the drug is to make it part of a monthly routine in which patients could use a a pen-like device and inject themselves on the upper thigh or abdomen. About 14 million people are defined as chronic sufferer... |
| 19.04.2012 | Alder BioPharmaceuticals Inks $38M Series D | BOTHELL, WA, Series D financing to support the development of the company's clinical stage pipeline. The financing was led by a new investor, Novo Ventures. >> Click here for more funding data on Alder BioPharmaceuticals >> ... |
| 19.04.2012 | Alder BioPharma raises $38M for cancer, migraine research | In one of the largest venture capital rounds in the state so far this year, Bothell’s Alder BioPharmaceuticals has raised $38 million to support ongoing research for its cancer and migraine headache treatments. Investors in the deal include... |
| 19.04.2012 | Alder BioPharmaceuticals Closes $38M Series D Financing | Alder BioPharmaceuticals Inc., Bothell, Wash.-based developer and manufacturer novel antibody therapeutics for cancer, pain, cardiovascular and autoimmune and inflammatory disease areas, has closed a $38m Series D financing. The round was l... |
| 11.01.2008 | Alder Bio and its yeast-produced antibodies take in $40M | Alder Biopharmaceuticals, a Bothell, Wash., developer of antibody drugs, raised $40 million in a third funding round. Investors included Delphi Ventures, TPG Biotech, Sevin Rosen Funds, Ventures West, H.I.G. Ventures, and WRF Capital. Alder... |
Show more